The shares are listed on Nasdaq

Davis Polk advised the underwriters in connection with the $140 million upsized initial public offering of 8,750,000 shares of common stock of Maze Therapeutics, Inc., at $16.00 per share. The common stock is listed on the Nasdaq Global Market under the ticker symbol “MAZE.”

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Elsie Cheang and Alexander Curtis. Partner David R. Bauer and associates Brette L. Trost and Jordan Khorshad provided intellectual property advice. The tax team included partner Ethan R. Goldman and associate Yueyu Yang. The executive compensation team included partner Adam Kaminsky and associate Laetitia Krisel. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post